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Systemic administration of Follistatin288
increases muscle mass and reduces fat
accumulation in mice
Samudra S. Gangopadhyay*
Section of Endocrinology, Diabetes, and Nutrition Department of Medicine Boston University School of Medicine 670 Albany Street,
Boston, MA 02118.
The present study describes the physiological response associated with daily subcutaneous injection of mice
with recombinant follistatin288. This systemic administration of follistatin288 increases the follistatin
levels in serum, indicating that the protein enters the circulation. The data suggest that a dose-dependent
increase in body lean mass also occurs, together with an increase in muscle mass, possibly as a result of an
increase in the size of themuscle fibers. After thirteen weeks of treatment,metabolic changes were observed;
additionally, the switching ofmuscle fiber types was also apparent throughmyosin heavy chain remodeling,
implying that changes are occurring at themolecular level. Furthermore, an increase in themusclemass was
associatedwith a significant decrease in the body fatmass. Overall, this study raises the possibility for the use
of follistatin288 as an agent to treat muscle wasting diseases and/or to restrict fat accumulation by systemic
administration of the protein.
T
he role of transforming growth factor-b (TGF-b)-mediated signaling has been well established in several
essential cellular and developmental processes, including differentiation, migration, proliferation, survival
and adult tissue homoeostasis1–3. TGF-b is a superfamily of cytokines that are ubiquitously expressed in a
range of species, fromworms and flies tomammals.Members of this superfamily function by binding specific cell
surface receptors (type I & II), which, in turn, activate the Smad proteins. The activated Smad proteins undergo
nuclear translocation and, together with other transcriptional co-activators and co-repressors, regulate the
expression of downstream target genes4,5. In addition to the canonical Smad mediated pathway, TGF-b proteins
also mediate other non-Smad pathways, including MAP Kinase, p53, PI3/Akt, JNK and NFkB pathways6,7.
Furthermore, the diversity of TGF-b functions arises through its regulation at multiple levels, beginning at the
ligand, the receptor and also the level of the transcriptional activation complex formation3,8. Within the TGF-b
superfamily, the activity of the growth and differentiation factor (GDF) family proteins has drawn increasing
attention. The GDF family was discovered to have possible therapeutic applications in the treatment of muscle
wasting diseases or muscle loss conditions that are associated with other pathological conditions, including
obesity and aging. In this regard, the discovery of GDF-8 (popularly known as myostatin) as a negative regulator
of muscle growth raises the possibility of developing new targets to limit its function in the body, thereby
facilitating muscle growth9,10. The use of multiple pharmacological inhibitors to block the activity of myosta-
tin11–14, as well as genetic alteration studies15,16 in animals, is very inspiring, and several clinical trials targeting this
pathway to treat muscle wasting are ongoing. However, the recent development of endogenous TGF-b inhibitory
proteins provides new insight into the regulation of TGF-b function in muscle development. In this regard,
Follistatin (FST), a potent myostatin antagonist, seems a good candidate with potential for use as a therapeutic
agent. FST antagonizes myostatin activity by binding to it and also by interfering with the binding of myostatin to
its receptor17–19, but in vivo studies indicate that myostatin may not be the only regulator of muscle mass and may
not be the only target of FST19. Direct interaction between follistatin and myostatin has been established17 and
inhibition of TGF-b signaling by follistatin has been reported20. The actual mechanism of action of FST is unclear,
but the use of FST to stimulatemuscle growth has been considered for therapeutic application13,21,22. In the present
study, the strategy was to introduce recombinant FST288 into animals via daily subcutaneous injection.
Continuous monitoring of the physiological response associated with the daily injection showed an increase in
the lean mass in a dose-dependent manner, and by thirteen weeks, a significant increase in the muscle mass was
observed. The results indicate that the increased muscle mass is caused by an increase in the average size of the
muscle fiber. Moreover, a switch in the muscle fiber type was observed as a result of myosin heavy chain
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remodeling. The study is also significant as there was a concomitant
loss of fat mass along with a gain of lean body mass, which is indi-
cative of a healthy metabolic condition.
Results
Recombinant FST288 is biologically active.N-terminal His-tagged
human FST288 was expressed in E. coli and purified by one-step
purification using a HisPur cobalt column, yielding almost 90%
pure protein, as determined from the Coomassie blue-stained gel
image (figure 1A). The protein was then purified with a Detoxi-
Gel column to remove bacterial endotoxins, which resulted in an
approximately 25-fold decrease in the endotoxin level, as deter-
mined by the Toxin Sensor LAL endotoxin assay (GenScript,
USA). The final endotoxin concentration in the protein prepara-
tion was approximately 0.04–0.06 E.U./ml (figure 1B); the protein
can be considered as ‘endotoxin free’ as this is a very low
concentration, within the recommended safety levels (Study of
McIntyre and Reinin, BD Biosciences). A cell proliferation analysis
of a plasmacytoma cell line, MPC-11, was performed to test the
biological activity of recombinant FST28823. Growth inhibition was
observed in the presence of 0.1–10.0 ng/ml activin in the growth
medium (figure 1C), as assessed by the decrease in 3H incorpora-
tion. However, the presence of increasing amounts of FST288 (1–
200 ng/ml) in the growth medium blocked the growth-inhibitory
effect of 5.0 ng/ml activin in a dose-dependent manner (figure 1C).
The injected recombinant FST288 enters the systemic circulation.
The level of follistatin in the serum of each animal was tested at the
end of week 13: 0.2 ml of serum (diluted to 20 ml) was separated with a
12% SDS-PAGE gel, and the separated proteins were transferred to an
Immobilon-Fl membrane (Millipore). Subsequent immunodetection
with the anti-follistatin antibody (k-19) showed a single band with
variable signal intensity between the different groups (figure 2A). The
mobility of the protein bandmatches that of the recombinant purified
protein loaded in the right lane. A densitometric analysis of the
average signal intensity from each group shows that the FST 100
group has an approximately 2.41-fold higher follistatin level in the
serum than the FST 0 control group. The densitometric analysis of
the FST 30 & 10 groups does not show significant differences
from the control group, but a dose-dependent effect on the serum
follistatin level was detected (figure 2B). These results indicate that the
injected FST288 enters the systemic circulation. The possibility of any
major degradation of the protein while in circulation was ruled out
based on the absence of smaller protein bands in the serum western
blot. Consistent with previous studies that have described the
presence of one single isoform, FST315, in the blood circulation24,25,
only a single band was detected from the serum of the animals in the
FST 0 group (figure 2A). However, two separate bands of endogenous
and injected recombinant FST288 were difficult to detect in the serum
of animals that received FST288. This result could be due to the
identical mobility of His-tagged FST288 and endogenous
follistatin315. Accordingly, western blot analysis of serum using the
anti-His-tagged antibody could only detect FST288, whereas the
signal from the serum of the FST 0 group was undetectable
(figure 2C).
Daily administration of FST288 causes a change in the body
composition in a dose-dependent manner. Body weight and body
composition were assessed at the beginning of the experiments, and
the values obtained were used as baseline for subsequent analyses. As
shown in figure 3A, on average, there is approximately a 19%
increase in the body weight during the course of 13 weeks in the
control group (FST 0), which did not receive FST288. However,
compared to the control group, body weight gain is significantly
lower at the end of 13 weeks in all three groups that received
FST288 (figure 3A). Among the three groups that received
FST288, the FST 100 group showed the highest weight gain
(10.7%). At the end of drug administration, the lean mass/fat mass
ratio in the FST 0 group had significantly decreased from baseline,
whereas in the FST 100 group, the ratio significantly increased
(figure 3B).
Themeasurement of leanmass shows a progressive increase in the
FST 100 group, whereas the FST 0 group shows a progressive
decrease over time (figure 3C). After 13 weeks, compared to the
FST 100 group, the lean mass content of the animals in the FST 0
group was lower than their baseline values, despite a significant
increase in their body weight (figure 3A). The average baseline values
were not significantly different among the four groups. There were
no significant differences in the leanmass contentmeasured from the
5th week onwards between the FST 10 & 30 groups, in contrast to the
FST 0 and FST 100 groups, which are significantly different
(figure 3C). In fact, the ratio of the lean mass/body mass for FST 0
after 13 weeks is lower than the ratio at baseline, as observed in
figure 3D. However, animals receiving FST288 showed an increase
Figure 1 | Recombinant FST288 is biologically active. (A) Coomassie blue stained full-length gel image of purified FST288 (left panel), and western blot
probed with the anti-FST antibody (right panel). (B) Endotoxin in the protein preparation. The amount of endotoxin was determined (dotted line) from
a standard curve in the assay. (C) Activin-induced inhibition of the MPC-11 cell proliferation is blocked by the addition of increasing amounts of
recombinant FST288 in the presence of 5 ng/ml activin.
www.nature.com/scientificreports
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in the lean mass/body mass ratio, and a dose-dependent response
was observed in all three experimental groups (figure 3D). In contrast
to the lean mass, there was a progressive increase in the fat mass in
the FST 0 group during the experiment, and interestingly, the fat
mass in the FST 100 group was found to decrease following admin-
istration of FST288 (figure 3E). The decrease in the fat mass in
the FST 100 group appeared significantly different from that in the
FST 0 group from the 9th week onwards; however, the fat mass of the
FST 10 and 30 groups appeared significantly different from that of
the FST 0 group only at the end of the 13th week. Additionally, the
measurement of fat mass/body mass ratio at the end of the course of
administration demonstrated an increase in the amount of fat accu-
mulation in the FST 0 group during the 13 week experiment but a
decrease in the FST 100 group (figure 3F). The difference in the ratio
between the FST 30 & 100 groups and the FST 0 group is statistically
significant, and the average values indicate a dose-dependent effect
on fat loss in the three experimental groups (figure 3F). A compar-
ison of the ratio of leanmass/bodymass and fatmass/bodymass data
(figure 3D & 3F) demonstrated that the administration of FST288
stimulates lean mass gain while reducing fat accumulation in the
body at the same time in a dose-dependent manner.
Postmortem dissection of tissues indicates muscle growth with
decreased fat accumulation. At the end of 13 weeks, FST288 admi-
nistration was stopped, and the animals were euthanized. Individual
tissues were removed and weighed and then preserved for further
analyses. As mentioned earlier, animals receiving 100 mg/day
FST288 showed the maximum effect of all tested doses on the
body composition measurements; this result prompted the deci-
sion to analyze tissue specific changes between the FST 100 and
FST 0 groups (control). Analysis of the individual muscle weights
of the hind limbs of the animals demonstrated a significant increase
in weight in the levator ani (approximately 34%), gastrocnemius
(approximately 41%), and extensor digitorum longus muscle
(EDL) (approximately 29%) in the FST 100 group compared to the
control group (figure 4A). Additionally, a 8–18% weight increase in
the tibialis anterior, soleus and quadriceps muscles in the FST 100
group was observed. Although weight gain was observed in the
kidney and prostate tissues in the FST 100 group animals, the
variability rendered the difference non-significant. The combined
data indicate that there is an increase in the muscle mass in the
FST 100-treated animals. The increase in the dissected muscle
mass was validated by a visual comparison between the FST 100-
treated mice and control mice (figure 4B–J). A comparison of the
abdominal visceral fat accumulation in the FST 100 group shows a
marked difference (figure 4) from the control animals, consistent
with the fat mass data obtained by EchoMRI analysis.
FST288 administration induces muscle fiber hypertrophy with
myofiber remodeling. To understand the anatomical changes in
the muscle fiber organization, a histological analysis was performed
on three isolated muscle tissues, namely, the gastrocnemius, tibialis
anterior and EDL. Frozen cross-sections (8 mM) from the midbelly of
each muscle were immunostained with the anti-laminin antibody,
and the area within the laminin stained fibers was determined
using Vision assistant software. Approximately two thousand fibers
randomly selected from tissues belonging to the same group were
analyzed, and the frequency distribution of the fiber area for all three
muscles was plotted (figure 5A, B & C). Compared to the FST 0
group, the FST 100 animals demonstrated an increase in the
average number of fibers with higher cross-sectional area in the
distribution of all three muscles. Moreover, the average fiber area
of the FST 100 group was significantly higher than that of the FST
0 group muscles (figure 5D, E & F) (approximately a 11%, 13% and
23% increase in the tibialis, gastrocnemius and EDL muscles,
respectively). This observation indicates that there was hypertrophy
of the muscle following FST288 treatment and that caused the
increase in muscle mass. The total number of fibers was not
significantly different in the control and FST 100 group muscles
(tibialis and EDL) (data not presented).
Skeletal muscle fibers are heterogeneous in terms of their size, fiber
type and activity. This heterogeneity fulfills a variety of functions by a
variety ofmuscles in the body; however, in response to changes in the
metabolic activity and/or performance demand, skeletal muscles
undergo remodeling of the fibers to meet functional requirements.
To understand the changes in the myofiber type in the FST 100
treated animals, immunohistochemistry was performed using myo-
sin heavy chain (MHC) isoform specific antibodies in the three
muscles gastrocnemius, tibialis and EDL. Skeletal muscles are com-
posed of four types ofmyosin heavy chain isoforms (type I and IIA, B
Figure 2 | FST288 in the systemic circulation. (A) Western blot (full-
length) of serum probed with the follistatin antibody (upper panel).
Recombinant FST288, used as the control, is detected in the blot and
labeled as R-FST. Bands of serum albumin, assessed as a loading control,
are presented in the lower panel. (B) The densitometry of the average
western blot signals from each group as obtained in A. The fold change
with respect to the FST 0 group is presented above the bar. (C) Western
blot (full-length) of serum from three animals of three groups, as indicated,
probed with the anti-His antibody. * and *** indicate p , 0.05 and
,0.001, respectively.
www.nature.com/scientificreports
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& X), and isoform-specific mouse monoclonal antibodies were used
for immunodetection. It should be noted that the isoform specific
antibodies were raised in mice, thereby restricting the ability to co-
stain a single muscle section for multiple isoforms. As a result, con-
secutive sections from the samemuscle were stained withMHC I and
IIA, B & X-specific monoclonal antibodies separately and co-stained
with laminin and DAPI. As shown in figure 6, a change in the dis-
tribution of theMHC isoforms was observed in the muscles from the
FST 100 group compared to the FST 0 group (see Supplementary
figure S1–S3). Thus, the data suggest that in the gastrocnemius and
tibialis, MHCI, MHCIIA & X are present in clusters in specific
regions of the muscle, whereas MHCIIB is ubiquitous. However,
EDL presents an almost homogenous distribution for all MHC
isoforms tested. Careful observation indicates that compared to the
FST 0 group, the number of MHC I & IIA fibers decreased and the
number of MHCIIB fibers increased in all three muscles tested in
the FST 100 group. However, the numbers of MHCIIX fibers either
increased or were not affected by FST 100 administration.
FST288 administration alters the metabolic rate and activity of
mice. To understand changes in the physiochemical status and
activity of animals that result from FST288 treatment, metabolic
measurements were performed on four animals from each of the
FST 0 & 100 groups. The volume of oxygen consumption (VO2)
and the volume of carbon dioxide (VCO2) production were
calculated based on the fraction of gas passing through the input
Figure 3 | Growth and change in body composition in response to FST288 administration tomice. (A) Time course of the average body weight from all
four groups, as indicated, represented as the percent of baseline. (B) Lean mass/fat mass ratio of animals, as indicated, after 13 weeks of treatment
with FST288. (C & E) Time courses of lean mass and fat mass measurement, respectively, during the period of FST288 administration, plotted as the
percent of body weight. (D & F) Lean mass/body mass and fat mass/body mass, respectively, of animals, as indicated, after 13 weeks of administration of
FST288, plotted as the change (difference) from the baseline values. *, ** and *** indicate p , 0.05, ,0.01 and ,0.001, respectively. p-value
measurements in A, C and E are between FST 0 and FST 100.
www.nature.com/scientificreports
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and at the exhaust point along with the air flow through the cage. An
integrated program conducted the experimental operation and data
collection. The data analysis indicated that the VO2 of the FST 100
group was significantly lower than that of the control animals
(figure 7A). The respiratory exchange ratio (RER) is an indicator
of metabolism that describes which fuel (carbohydrate or fat) is
utilized to supply the body with energy, and it is calculated as the
ratio of the volume of CO2 produced over the volume of O2
consumed (VCO2/VO2). The RER value is 1.0 when only carbohyd-
rates are utilized, and the ratio is 0.7 when fat is predominantly
utilized as the fuel source to supply the body with energy. The
average RER value for the FST 100 group animals was significantly
increased compared to that for the FST 0 group animals, as shown in
figure 7B. This observation indicates that after 13 weeks of admini-
stration, the FST 100 group animals use glycolytic metabolism more
than oxidative metabolism, which is consistent with the observed
decrease in fat mass in the body. Total body energy expenditure is
calculated as the equivalent of heat produced, which is determined
from the RER and O2 consumption values by a method known as
indirect calorimetry. These data indicate that the energy expenditure
of the FST 100 group animals was significantly lower (approximately
15%) than that of the control animals (figure 7C). To correlate the
metabolic rate with physical activity, spontaneous locomotor activity
measurements (X-axis ambulatory activity) were performed. As
shown in figure 7D, the X-axis ambulatory activity of the FST 100
animals was significantly higher (approximately 21% higher) than
that of the control animals.
Discussion
The present study describes the expression of the protein follistatin
288 (FST288) in E. coli. This protein was found to be biologically
active and enters the systemic circulation after subcutaneous injec-
tion. The increased amount of FST288 in the serum of animals
receiving a higher dose of FST288 indicated that the exogenous
recombinant protein level in the serum can be altered by varying
the amount of protein administered and that, more importantly, the
Figure 4 | Post-mortem observation of muscles and organs. (A) Average weights of the dissected tissue, as indicated, of the FST 100 group
presented as the percent of the FST 0 group (normalized to body weight). * and ** indicate p , 0.05 and ,0.01, respectively. Pictures of lower limb
(B, C and D), upper limb (E), facial (F), abdomen (G) abdominal visceral fat (H), dissected levator ani (I) and prostate (J) representing control (FST 0)
and FST 100 groups, as indicated.
www.nature.com/scientificreports
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injected FST288 circulated in the body without undergoing degra-
dation (as revealed by gel electrophoresis mobility) (figure 1 and 2).
Many physiological responses resulted from FST288 administra-
tion. First, a progressive effect was observed over the course of
administration. However, continuous monitoring of the mice indi-
cated that the weight gain by the control group (which did not
received FST288) was greater than that of the experimental groups.
The lean mass/fat mass ratio became progressively lower for the
control group (FST 0) over the course of the experiment, whereas
this ratio increased in a dose-dependentmanner for the experimental
groups (Figure 3). More specifically, the data indicate that the loss of
fat mass is associated with muscle mass gain.
The function of follistatin as a stimulator of muscle mass has been
established in transgenic animals, but the current study indicates that
the muscle mass gain is also associated with a concomitant fat loss.
The fat loss was revealed by EchoMRI measurements, in addition to
the visual difference in the visceral fat accumulation between the
control and the FST 100 group animals. Furthermore, this study
clearly indicates that follistatin is also a regulator of fat metabolism.
The increase in muscle mass is possibly due to the increase in the
average muscle fiber size (figure 5). Additionally, the data suggest
that follistatin treatment modifies the muscle contraction machinery
at the molecular level. Skeletal muscle is composed of four types of
muscle fibers26–28, which can be distinguished based on the express-
ion of four MHC isoforms (MHC I, IIA, IIB and IIX)29,30. Type I and
IIA fibers are employed for slow twitches, whereas type IIB and IIX
fibers are utilized for the fast movement of the muscle. The ratio of
the four types of fibers present in the skeletal muscle varies in the
muscle groups present in the body. Furthermore, the dynamic nature
of the fiber types is due to alteration of their relative ratios in response
to muscle activation, such as exercise, electrical stimulation, or in
response to hormonal stimulation. MHC isoform types have been
reported to switch in skeletal muscles depending on the physical
demands29,31, and the remodeling of MHC compositions has been
established to occur, by multiple experimental approaches, although
the underlying mechanism is not yet clear. A combination of in vivo
and in vitro studies indicates that intracellular calcium release in
response to motor neuron stimulation plays a vital role in regulating
calcineurin activity. Slow twitch fibers maintain a higher level of
Figure 5 | Muscle fiber area distribution of animals in the FST 0 and FST 100 groups. (A, B and C) Frequency distribution of areas from laminin
stained muscle fibers, as indicated. (D, E and F) Average area of corresponding muscle fibers, plotted as a percent of the FST 0 group. Representative
images of fiber area are presented in the inset. * and ** indicate p , 0.05 and ,0.01, respectively.
Figure 6 | Analysis of muscle fiber types in muscles. Isoforms of the
myosin heavy chains (MHC) stained with specific monoclonal antibodies
(red) and co-stained with laminin (green), as indicated.
www.nature.com/scientificreports
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calcium, causing increased activation of calcineurin than fast twitch
fibers, which, in turn, dephosphorylates transcription factors of the
NFAT (nuclear factor of activated T cells) family. Dephosphorylated
NFAT translocates to the nucleus and upregulates slow fiber specific
gene expression. By contrast, decreased activation of calcineurin
promotes the transition of slow-to-fast myofibers31,32.
Metabolite utilization also varies depending on the types of fibers
present in themuscle. Type I and type IIAmuscle fibers (slow twitch,
high endurance) utilize oxidative metabolism, whereas type IIB and
IIX fibers (fast twitch, low endurance) have a preference for glyco-
lytic (anaerobic) metabolism26,27,29. The observation that the number
of type IIB (also possibly IIX) fibers has increased and the numbers of
type I and IIA fibers has decreased by the end of the current experi-
ment defines a direct relationship with the increased RER values.
This result further indicates that when the fat mass significantly
decreases, glycolytic metabolism (utilization of carbohydrate) is pre-
ferred (figure 6 and 7). The overall metabolic activity measurement
suggests that FST288 administration may promote high power/
speed/force production for short sprints. The increase in muscle
mass, as observed from the selected dose used in the systemic admin-
istration of FST288, is not as robust as that observed in transgenic
animal studies18. Moreover, optimization of the dose and duration of
administration may improve the drug’s efficacy.
FST288 was selected instead of the other follistatin isoform
(FST315) because FST315 is a free circulating isoform that lacks
the ability to bind to cell surface proteoglycans24,25. It will be inter-
esting to determine whether FST315 has a similar in vivo effect to
FST288 using the same methods as in this study, although the func-
tion of FST315 has also been tested in rodents and nonhuman pri-
mates by gene therapy approaches22,33. Thus, the isoform specific
function of follistatin in the regulation of muscle and fat mass
remains to be clarified. The histology of adipose tissue is of signifi-
cant interest to understand FST mediated change in morphology as
well as accumulation of lipid droplets in the adipocytes and future
study will proceed to that direction.
Themost important observation of the current study is the physio-
logical response detected to the injected recombinant protein, which
leads us one step closer to the therapeutic administration of follista-
tin. The use of steroids as a stimulator of muscle mass is common
amongst athletes, but the associated adverse effects restricts steroid
use for the treatment of muscle degenerative diseases as well as of age
related mobility limitations34–37While scientists are trying to develop
Selective Androgen Receptor Modulators (SARMs), follistatin could
be a new candidate for future therapeutic application. Moreover,
systemic administration as utilized in the current study has several
advantages for clinical applications. With a daily injection, the doses
can be controlled, and the drug can be administered as needed. Thus,
overall, the study opens up the possibility of testing FST288 as a
therapeutic agent to reverse muscle wasting conditions and aids
our understanding of the functional mechanism of follistatin.
Methods
Expression and purification of human FST288. Follistatin 288 (FST288, amino acid
residue no. 30–317) cDNAwas cloned into the Sal1/Xho1 site of pET30 and expressed
with a His-tag in E. coli BL21(DE3) by induction with IPTG. The cells were then
resuspended in buffer containing 100 mM Tris-HCl, pH 8.0, and 10 mM NaCl and
were sonicated on ice. The insoluble portion of the lysed cell suspensionwas separated
by centrifugation, and the pellet was solubilized with a buffer containing 50 mMTris-
HCl, pH 8.0, 8 M urea and 100 mM PMSF. His-tagged FST288 was purified with a
HisPur cobalt spin column (Thermo scientific, Rockford, IL) according to the
manufacturer’s instructions. The purified protein, in elution buffer containing 8 M
urea, was diluted (154) with 200 mM Tris-HCl, pH 10.0, and 2 mM DTT and
incubated on ice for 4–5 hours. The diluted protein was dialyzed against Tris buffer
(10 mM Tris-HCl, pH 8.0, and 1 mM NaCl) or PBS at 4uC, with several
modifications. The purified protein was subsequently passed through Detoxi-Gel
(Endotoxin Removal Gel), Thermo Scientific, to remove bacterial endotoxins and
stored at 280uC with 15–20% glycerol.
Activity assay of the recombinant FST288. The biological activity of the
recombinant FST288 was assessed by testing its ability to neutralize the growth
inhibitory effect of activin onmouseMPC-11 cells, as described previously by Phillips
et al23. Briefly, 1000 viable cells were seeded per well in a 96-well plate in a volume of
0.1 ml DMEM supplemented with 10% fetal calf serum, Pen-Strep and 25 mM b-
mercaptoethanol. Activin (Stemgent, MA) or recombinant FST288 in the presence of
activin was added, as indicated, to the culturemedium, and cells were allowed to grow
for 48 hours. Finally, 0.25 mCi of [3H] thymidine (6.7 Ci/mmol) was added to each
well, and the cells were incubated for another 24 hours. The incorporation of [3H]
thymidine into the cells was measured with a Cerenkov counter.
Animal experiments. Animal experiments were conducted in accordance with the
guidelines established and approved by the Institutional Animal Care and Use
Committee (IACUC) of Boston University. Eight weeks old C57BL/6 mice were
obtained from Jackson Laboratory (BarHarbor,Maine) and housed in the Laboratory
Animal Science Center (LASC) of Boston University Medical Center. Animals were
allowed to recover for one week in the animal facility prior to the start of the
experiments.
The recombinant FST288 in PBS containing 20% glycerol was subcutaneously
injected into each animal daily for 13 weeks in a volume of 100 ml for all doses. The
experiment was performed on four groups of animals with six individuals per group.
The four groups were FST 0, 10, 30 and 100, with a daily FST administration of 0, 10,
30 and 100 mg per animal, respectively.
Body composition. The body composition was assessed by two methods: 1) NMR
using the EchoMRI-700 instrument and 2) postmortem dissected tissue weights.
An EchoMRI-700 (Body Composition Analyzer) from Echo Medical System
(Houston, TX) was used to determine the fat mass and lean mass on a weekly basis in
conscious, un-anesthetized animals. The body weight of each animal was measured,
and the animals were placed individually into a plastic holder with limited restraint.
Each scan took approximately 1–2 min. For postmortemmeasurement ofmuscle and
other tissue weights, the individual muscles/tissues from each animal were dissected
at the end of the 13 week administration, and the average weight was presented.
Muscle morphometry.Dissectedmuscle, frozen with OCT compound, was cut at the
midbelly, and 8 mm sections were transferred to glass slides. The sections were
subjected to immunohistochemistry for laminin (rabbit anti-laminin Ab-1 antibody
fromNeoMarkers, Fremont, CA) to outline the muscle fibers for the measurement of
fiber areas. For fiber typing, myosin heavy chain specific monoclonal antibodies were
obtained from Developmental Studies Hybridoma Bank, University of Iowa. Type I
(BA-D5), type IIA (SC-71), type IIB (BF-F3)38 and type IIX (6H1) antibodies39 were
used, along with laminin for co-staining. Nuclei were stained with DAPI, and the
images were acquired using the Eclipse TE 2000-U fluorescence microscope (Nikon
Instruments Inc., Melville, NY). The fiber area measurements were performed using
the Vision assistant software (National Instruments, Astin, TX).
Figure 7 | Metabolic measurements of the FST 0 and FST 100 group
animals. Comparison of oxygen consumption (VO2) (A) respiratory
exchange ratio (RER) (B) energy expenditure (heat) by indirect
calorimetry (C) and X-axis ambulatory activity (D) between the FST 0 and
100 groups at the end of 13 weeks of FST288 administration. * and ***
indicate p , 0.05 and ,0.001, respectively.
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Metabolic assessments. Indirect calorimetry was utilized to examine oxygen
consumption (VO2) and carbon dioxide production (VCO2) of individual mice for
24 hours in the fed status using a comprehensive laboratory animal monitoring
system (CLAMS) equipped with an Oxymax Open Circuit Calorimeter (Columbus
Instruments, Columbus, OH). VO2 and VCO2 values were used to calculate the
respiratory exchange ratio (RER) and energy expenditure (heat - kcal/hr).
Spontaneous locomotor (ambulatory) activity was recorded at the same time with
indirect calorimetry using the Opto M3 multi-channel activity monitor (Columbus
Instruments, Columbus, OH). The data were analyzed using Oxymat for Windows
(V4.2) software.
Western blotting. From each animal, at 13 weeks of FST288 administration, 0.5 ml of
serum was , electrophoresed on a 12% SDS-PAGE gel, and the separated proteins
were transferred to a PVDF membrane. The blot was probed with an anti-FST-
antibody (K-19) from Santa Cruz Biotechnology, CA. The His-tag was detected by
probing the blot with an anti-His antibody from Cell Signaling, MA.
Statistical analysis. Experimental calculations for the activity assay, body
compositions and metabolic activity measurements were performed using Microsoft
Excel software. Muscle fiber distribution was determined using Prism software
(Graphpad). The bodyweight and body composition values obtained at the beginning
of the experiment were considered a baseline for subsequent analyses. Body weight
gain was represented as the percent of the respective baseline values, and leanmass or
fat mass was presented as the percent of the body weight. Dissected tissue weights
were presented as the percent of control tissue (FST 0) weights.
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